GeoVax to Present Single-Dose MVA and Continuous Cell-Line Manufacturing Advances at World Vaccine Congress Europe 2026

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, announced that Dr. Senthil Ranganathan, Vice President of Technical Development and CMC Operations, will present at the World Vaccine Congress Europe 2026, taking place October 19–22 at the RAI Amsterdam. His presentation, “Revolutionizing MVA – Single Dose and Continuous Cell-Line Manufacturing,” will highlight the company’s progress in advancing next-generation Modified Vaccinia Ankara (MVA) technologies. The talk will focus on two complementary goals: achieving robust immunity with a single vaccine dose and establishing a scalable continuous cell-line manufacturing platform. This news was originally distributed via NEWMEDIAWIRE.

GeoVax’s MVA-X technology is designed to enhance immune responses and enable effective vaccination after just one administration. Preclinical studies have shown protective immune responses following a single dose, with data presented earlier this year at the World Vaccine Congress Washington demonstrating that a single administration of MVA-X achieved protective efficacy comparable to a traditional two-dose MVA regimen in a murine orthopoxvirus challenge model, with protection maintained through Day 150. In parallel, GeoVax is advancing MVA production using the AGE1.CR.pIX continuous avian cell line as an alternative to traditional chicken embryo fibroblast-based manufacturing. The company has demonstrated proof-of-concept for the upstream process, and the downstream process is in development to support production at the 200-liter scale, with a pathway toward 500-liter and larger-scale manufacturing. This approach aims to enable scalable, reproducible production, reduce reliance on primary-cell supply chains, and facilitate technology transfer.

David A. Dodd, Chairman and CEO of GeoVax, commented, “MVA is an important and well-established vaccine platform, and we believe there are significant opportunities to further improve how MVA-based vaccines are administered and manufactured. Our work with MVA-X and AGE1.CR.pIX addresses both sides of that equation - potentially simplifying vaccination through a single-dose approach while establishing a scalable manufacturing platform capable of supporting broader and more responsive vaccine supply.” Dodd continued, “Senthil’s participation in the Platform Technologies workshop at World Vaccine Congress Europe provides an important opportunity to share GeoVax’s progress with the global vaccine community. Bringing together next-generation vaccine design and scalable manufacturing has potentially important implications for outbreak response, pandemic preparedness, biodefense, strategic stockpiling, and expanded global access to MVA-based vaccines.” For more information, visit www.geovax.com.